and Cancer Guardian

What Life Insurers are Saying About Cancer Guardian

Supporting Longer, Healthier Lives

The odds are sobering.  Cancer is presently the 2nd leading cause of death claims, and Americans born today have a 50% risk of being diagnosed with cancer during their lifetime.(1)  Most will be unprepared to navigate the complexities of health care systems to ensure the best treatment options for positive outcomes.   Cancer Guardian has been developed to address the complexities of navigating the cancer journey to support longer, healthier lives.

Prevention and treatment - it's in the DNA

Prevention and Treatment – it’s in the DNA

Cancer is a complex genetic disease.  Cancer Guardian provides both hereditary cancer screening to help prevent cancer, and comprehensive genomic profiling if diagnosed with cancer.  Studies have shown that early detection contributes to improved survival rates.  In breast cancer, early detection drives a 4x improvement in five-year survival rates.(15)

Navigating cancer with expert support

Navigating Cancer with Expert Support

In a recent survey, 47% of cancer patients/caregivers indicated that there was “no knowledgeable advocate to help” in finding an effective treatment or solution.(16)  Cancer Guardian provides dedicated Cancer Support Specialists to provide support and resources through each step of the cancer journey for improved outcomes.

Affordable access to advanced cancer services

Affordable Access to Advanced Cancer Services

Cancer Guardian solves the problem of awareness, access and affordability to services that can help improve prevention and survival.  It democratizes cancer care by providing members with the advanced DNA testing and support services typically limited to those with the means and the connections to access.

Offer Policy Holders Affordable
Comprehensive Cancer Support.

Contact Us Lead Insurers


1. Lifetime Risk of Developing or Dying from Cancer Basic Facts.  American Cancer Society, 2019.

2. Wamberg Genomic Advisors, Cancer Survey of 204 cancer patients and nonprofessional advocates.  Survey Sampling International (SSI), 2018.

3. Unger, Joseph M., et al. Systematic Review and Meta-Analysis of the Magnitude of Structural, Clinical and Physician and Patient Barriers to Cancer Clinical Trial Participation.  JNCI J NATL Cancer Institute, 2019.

4. Family Reach. Annual Report 2016. Family Reach Foundation https://familyreachorg/wp-content/uploads/
2017/05/ frf_2016_annual_report_compressedpdf Accessed July 30, 2017.

5. CancerCare. Cancer Care Patient Access and Engagement Report. New York: CancerCare. 2016.

6. Manchanda, Ranjit, et al.  Population based germline testing for primary cancer prevention.  Oncotarget, 2018, Vol. 9 (No. 69), pp: 33062-33063

7. Waszak, Przemyslaw M. et al.  The Spread of Medical Fake News in Social Media.  Health Policy & Technology Review, Elsevier, 2018.

8. Stephen S. Raab, Dana M. Grzybicki, CA Cancer J. Clin. 2010 May-Jun,60(3): 139-65

9. Raab, Stephen S. MD, et al. Quality in Cancer Diagnosis.  Cancer J. Clinical 2010

10. J. Unger, et al., Systematic Review and Meta-Analysis of the Magnitude of Structural, Clinical and Physician Barriers to Cancer Clinical Trial Participation, JNCI J Natl Cancer Inst 2019

11. The State of Cancer Care in America, 2014: A report by the American Society of Clinical Oncology.  Journal of Oncology Practice, 2014; 10(2):120-122

12. Sun Life Stop-Loss Report, 2019.


14. Measuring Health-Related Productivity Loss.


16.  Wamberg Genomic Advisors Cancer Survey of 204 cancer patients and nonprofessional advocates fielded by Survey Sampling International (SSI), 2018.  Available at:

Informational Resources